Overview

NCI Definition [1]:
A peptide vaccine containing a 15-mer peptide (DLAQMFFCFKELEGW), with C to M alteration at amino acid position 57, derived from the anti-apoptosis protein survivin, and conjugated with keyhole limpet hemocyanin (KLH), with potential immunopotentiating and antineoplastic activities. Upon subcutaneous administration of SVN53-67/M57-KLH peptide vaccine, this peptide is able to bind both HMC class I and II molecules and may activate the immune system to mount a cytotoxic T-lymphocyte (CTL) as well as a T-helper cell response against survivin-expressing cancer cells. This may result in decreased tumor cell proliferation and ultimately tumor cell death. Survivin, a member of the inhibitor of apoptosis (IAP) family, expressed during embryonic development while absent in most normal adult cells, is upregulated in a variety of human cancers; its expression in tumors is associated with a more aggressive phenotype, decreased survival, and increased resistance to chemotherapy. KLH may enhance immune recognition and may promote an enhanced response. As SVN53-67 is weakly immunogenic in humans, the M57 alteration may lead to greater affinity towards HLA-A*0201 and thus an enhanced antitumor immune response.

Svn53-67/m57-klh peptide vaccine has been investigated in 3 clinical trials, of which 3 are open and 0 are closed. Of the trials investigating svn53-67/m57-klh peptide vaccine, 2 are phase 1 (2 open) and 1 is phase 2 (1 open).

BIRC5 Expression, HLA-A*02 Positive, and HLA-A*03 Positive are the most frequent biomarker inclusion criteria for svn53-67/m57-klh peptide vaccine clinical trials.

Gastrointestinal neuroendocrine tumors, glioblastoma, and gliosarcoma are the most common diseases being investigated in svn53-67/m57-klh peptide vaccine clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Svn53-67/m57-Klh Peptide Vaccine
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating svn53-67/m57-klh peptide vaccine and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
survaxm
Drug Target(s) [2]:
BIRC5
NCIT ID [1]:
C95705

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.